[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_96":97},"routes/item",{"_9":10},"item",{"_11":12,"_13":14,"_15":16,"_17":18,"_19":20,"_21":-5,"_22":23,"_24":25,"_26":27,"_28":29,"_30":29,"_31":32,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":-5,"_46":47,"_48":-5,"_49":-5,"_50":51,"_52":53,"_54":55,"_56":57,"_58":57,"_59":60,"_61":40,"_62":63},"id","jyvmefar4k4nn824899ygm827","revision",2,"title","XORTX Therapeutics Inc. 6-K 文件发布","originalTitle","6-K - XORTX Therapeutics Inc. (0001729214) (Filer)","summary","XORTX Therapeutics Inc. 发布 6-K 文件，披露公司财务信息。文件包含 2026 年 10 月的报告，由首席执行官 Allen Davidoff 签署。该文件为美国证券交易委员会提交的外国私人发行人报告。","reason","source",{"_11":86,"_87":88,"_89":90,"_91":57,"_92":93,"_94":95},"links",{"_83":84,"_63":85},"publishedAt","2026-10-08T20:07:27.000Z","discoveredAt","2026-10-08T23:27:43.428Z","timelineAt","category","tip","tags",[81,82],"stockSymbols",[80],"score",23,"selected",false,"channel","news","story",{"_72":73,"_15":74},"x","readingMode","full","author","language","body",{"_76":-5,"_63":77,"_78":-5,"_79":40},"outline",[],"relatedStories",[75],"indexable",true,"markdownAvailable","group",{"_64":65,"_43":66,"_67":68,"_69":70,"_71":70},"hasTranslation","bodyLanguage","original","factId","f_zPE7UjbyG8",{"_72":73,"_15":74},"reportCount",1,"additionalSourceCount",0,"developmentCount","publicId","72c70b77-dbe2-4ece-ba30-2862ab1e5507","多家公司提交2026年10月6-K财务文件",{"_72":73,"_15":74},"zh","

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2026

Commission File Number: 001-40858

XORTX Therapeutics Inc.

3710 – 33rd Street NW, Calgary, Alberta, Canada T2L 2M1

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F [ X ] Form 40-F [ ]

EXHIBIT INDEX

Exhibit		Description

99.1		News release dated October 8, 2026.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	XORTX Therapeutics Inc.


Date: October 8, 2026	By:	/s/ Allen Davidoff
	Name:	Allen Davidoff
	Title:	Co-Chief Executive Officer

","zhKind","complete","XRTX","政策与监管","退市","aihot","/items/jyvmefar4k4nn824899ygm827","https://www.sec.gov/Archives/edgar/data/1729214/000117184326006540/0001171843-26-006540-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","kind","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1791763200&sig=95a77c187c5dca32","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1791763200&sig=3a0fa885471986b2 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1791763200&sig=31c65723824c6538 96w","changelogVersion","2026-10-01T08:00"]